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Background: Patients with transitional cell carcinoma of the urothelial tract (TCCU) who fail initial platinum-based
chemotherapy for advanced disease represent a challenge in daily clinical practice. Vinflunine is approved by the
European Medicine Agency (EMA) but, up to now, limited experience has been reported outside clinical trials.
Methods: We assessed the efficacy and safety of vinflunine in an unselected group of 102 consecutive patients
with metastatic TCCU.
Results: The median age was 67 years (range 45–83). Among the most common comorbidities that patients
presented at baseline were hypertension (50.5%) and diabetes (20.7%).
Distant metastases were present in retroperitoneal nodes (58%), lung (29.3%), and bone (20.2%). The ECOG 0,
1 and 2 performance status at the start of vinflunine were 31.3%, 60.6% and 8.1%, respectively. The most
commonly reported adverse events of any grade were constipation 70.6% (5.9% grade 3–4), vomiting 49.1%
(2% grade 3–4), neutropenia 48.1% (12.8% grade 3–4) and abdominal pain 34.3% (4.9% grade 3–4). A median
of 4 cycles of vinflunine was administered per patient (range 1–18). Median progression free and overall
survival for all patients (N = 102) were 3.9 months (2.3-5.5) and 10 months (7.3-12.8), respectively. Time to
tumor progression was 4.3 months (2.6-5.9). Two patients (2%) achieved CR, 23 (22.5%) patients had PR, and
42 (41.2%) presented SD as best response. The clinical benefit rate with vinflunine was 65.7%.
Conclusions: Our results show that the behavior of vinflunine in routine clinical practice resembles that of
the pivotal phase III randomized study.
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Transitional cell cancer of the urothelial tract (TCCU)
represents a major health problem worldwide. In fact,
TCCUs are the sixth most common type of cancer in
western countries [1]. Traditionally, advanced TCCUs
have been considered chemosensitive tumors based on high
radiological response rates of 40-70% with cisplatin-based
schemes such as gemcitabine-cisplatin (GC), methotrexate,* Correspondence: egrande@oncologiahrc.com
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article, unless otherwise stated.vinblastine, doxorubicin, and cisplatin (M-VAC) or pacli-
taxel, cisplatin, and gemcitabine (PCG) [2-4]. Unfortu-
nately, responses are not maintained over time and median
progression free and overall survivals rarely exceed 8 and
15 months, respectively, when metastatic TCCU patients
are treated in first-line [5-8]. Patients who fail the initial
systemic approach for advanced disease represent a
challenge in daily clinical practice.
In the last decade, wide ranges of single agents or com-
bination schemes have been tested for activity in patients
who are resistant to previous platinum approaches. The
drugs explored in this setting included paclitaxel, [9] nab-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.biomedcentral.com/1471-2407/14/779paclitaxel, [10] irinotecan, [11] ixabepilone, [12] bortezo-
mib, [13] pemetrexed, [14] oxaliplatin, [15] ifosfamide, [16]
lapatinib, [17] docetaxel, [18] gemcitabine, [19] topotecan,
[20] gefitinib, [21] sorafenib, [22] sunitinib, [23] and pazo-
panib [24]. The most promising combined chemotherapy
schemes among those studied were paclitaxel plus gemci-
tabine, [25] ifosfamide plus gemcitabine [26] or carboplatin
plus paclitaxel [27]. Despite the great efforts and re-
sources devoted to all these trials, together with the num-
ber of patients involved, in most cases the clinical outcomes
were disappointing with objective response rates ranging be-
tween 10 and 20%, median progression free survivals of 2–3
months, and median overall survivals of 6–9 months [28].
Vinflunine is the newest member of the vinca alkaloids
family available to clinical practice [29]. As with other
tubulin inhibitors, vinflunine prevents microtubule assem-
bly during mitosis and induces apoptosis [30,31]. The main
differentiating feature that distinguishes vinflunine from
others vinca alkaloids is the affinity profile of vinflunine
which has a greater effect on mitotic rather than axonal
tubulin. Therefore, the result is a significantly reduced rate
of neurotoxicity which allows for greater plasma concen-
trations of the drug [32]. The clinical activity of vinflunine
in patients with metastatic TCCU was initially assessed in
two non-randomized phase II trials [33,34]. The earlier
phase II trials showed that the activity of vinflunine in 51
and 175 platinum-resistant TCCU patients achieved re-
sponse rates of 18% and 15%, respectively, and median
duration of responses were 9.1 and 6 months. Median pro-
gression free survival and overall survival were 3.0 and
6.6 months in the first trial, and 2.8 and 8.2 months in the
second one. These consistent results led to a pivotal, multi-
national, and randomized study that compared vinflunine
and best supportive care in second-line treatment of
advanced TCCU patients who had previously progressed
after a platinum-containing regimen [35]. A total of 370
patients were recruited and vinflunine was shown to be
superior to the control arm in terms of the considered
primary endpoint of the study which was overall survival in
the intention to treat population (6.9 months vs. 4.6 months).
However, these results were not found to be statistically
significant (HR 0.88; 95% CI, 0.69-1.12: P = 0.287).
All others efficacy parameters favored vinflunine
clinically and were statistically significant, such as over-
all survival in the analysis per protocol population (6.9
vs. 4.3 months: P = 0.04), overall response rate (16% vs
0%: P = 0.0063), disease control rate (41.1% vs 24.8%:
P = 0.0024), and median progression free survival
(3.0 months vs 1.5 months: P = 0.0012). The duration
of objective responses was 7.4 months (95% CI 4.5 to
17.0 months) in those patients treated with vinflunine.
Long-term overall survival data from this registration
trial after a follow-up of more than 45 months con-
firmed the increase in total median overall survival withvinflunine compared to best supportive care in the
intention to treat population (6.9 months vs. 4.6 months)
and the statistically significant increase in the eligible
population (6.9 vs. 4.3 months; HR 0.78; 95% CI 0.61-
0.96: P = 0.00227) [36]. As a result of this study, vinflu-
nine was the first drug to receive approval from the
European Medicine Agency (EMA) for use in platinum-
resistant metastatic TCCU patients. We conducted a retro-
spective, observational, and non interventional study
(according to the classification of the Spanish Health
Authorities) to assess the impact of treatment with vinflu-
nine in our daily practice in terms of toxicity, response
rate, duration of response, progression free survival, and
overall survival in an unselected subgroup of patients with
metastatic TCCU who had progressed after only one pre-
vious line of platinum-containing regimen for advanced
disease, and furthermore assessed the reproducibility of
the clinical trial results in routine clinical practice.
Methods
One hundred and two consecutive outpatients with meta-
static TCCU who were treated with vinflunine in 15 uni-
versity and community hospitals spread all along Spain
were analyzed for safety and activity. Patients started treat-
ment between December 2009 and June 2013, and follow
up and dose adjustments were performed according to
local investigators criteria. A normalized database with
uniform CRF’s adapted to urothelial cancer features, was
prepared for the data collection. Data were entered into
databases by the own investigators. Concerning to the eli-
gible population, it included adult patients with advanced
TCCU who had previously failed to one prior first-line
regimen based on platinum. All patients were offered for
systemic treatment with vinflunine for the advanced dis-
ease under approved conditions. Dose delays and dose
modifications were accepted according to the vinflunine
package insert. All patients signed the correspondent in-
form consent in accordance to good clinical practices and
local authorities regulation. The study was submitted for
validation in the Ethic Committee Hospital 12 de Octubre
as stated in the Royal Decree 223/2004 and Article 58 of
Law 29/2006 for Post Authorization Retrospective studies.
Moreover, it’s a clinical routine practice the use of an
Inform Consent for the patient to receive chemotherapy
and the use of their data under the personal data pro-
tection as detailed in the Spanish Data Protection Law;
Organic Law 15/1999 of December 13rd on the protection
of personal data.
Patients were deemed ineligible for the analysis if
they had received more than one previous chemother-
apy regimen for metastatic disease or had received any
non-approved chemotherapy agent after failure of a
platinum-based scheme. The study included the follow-
ing demographic variables: gender, age, prior cisplatin or
Table 1 Baseline characteristics of the study population
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approach, comorbidities, primary tumor location, patho-
logical details, surgery performed for the primary tumor, and
metastasis location. Objective clinical response [complete re-
sponse (CR), partial response (PR), stable disease (SD), or
progressive disease (PD)] was evaluated by Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1
through computed tomography (CT) scans. To evaluate
tumor response to treatment, thoracoabdominal CT scans
were performed according to the investigator’s routine
clinical practice. Univariate analyses of overall survival
and progression free survival were carried out using the
Kaplan Meier method, with test of statistical significance
performed using the log-rank test with 95% confidence
intervals.
Progression free survival was measured from the date
of consent to the use of vinflunine to either the date of
first objective evidence of disease progression or date of
death, whichever occurred first. Overall survival was mea-
sured from the date of consent to the use of vinflunine to
the date of death from any cause. Estimates of hazard ra-
tios were obtained using the Cox proportional hazards
model. Tests of statistical significance were carried out at
the 5% two-sided significance levels. All statistical analyses
were performed using the SPSS for Windows software
package (Rel. SPSS 14.0; SPSS Chicago, IL). The disease
control rate was defined as the percentage of patients
who had a best response rating of CR, PR, or SD.
Safety involved carrying out a toxicity assessment every
time a patient visited an investigators’ clinic or emergency
room. Adverse events were reported according to the
National Cancer Institute’s (NCI) Common Terminology
Criteria for Adverse Events (CTC AE; version 4.0).
Results
One hundred and two metastatic TCCU patients who
had previously failed one prior platinum-containing sys-
temic therapy were treated with vinflunine as a single
agent in a second-line setting. Baseline characteristics
are listed in Table 1. The median age was 67 years (range
45–83) and the majority of patients had the primary
tumor located in the bladder (83.2%). Among the most
common comorbidities that patients presented at base-
line were hypertension (50.5%) and diabetes (20.7%).
The majority of patients had urothelial carcinoma hist-
ology (88.2%) with a high degree of histological differen-
tiation (86.9%). Up to 73.5% of patients required at least
one previous transurethral resection for localized pri-
mary lesions. The most common locations for distant
metastasis were the retroperitoneal nodes (58%) followed
by lung metastasis (29.3%) and bone metastasis (20.2%).
When beginning vinflunine, 60% of patients had a per-
formance status of ECOG 1. Additionally, 31.3% and
8.1% of the patients presented ECOG 0 or 2,respectively. Previous platinum-based treatment in first-
line was split between cisplatin (47%) and carboplatin
(51%). Two patients had received paclitaxel plus gemci-
tabine as first-line treatment. A total of 57.9% had
achieved either PR or CR with a previous platinum-
based chemotherapy. All patients were included for the
assessment of toxicity. The most commonly reported
adverse events of any grade were constipation 70.6%
(5.9% grade 3–4), vomiting 49.1% (2% grade 3–4), neu-
tropenia 48.1% (12.8% grade 3–4) and abdominal pain
34.3% (4.9% grade 3–4) (Table 2). No toxicity-related
deaths were reported.
A median of 4 cycles of vinflunine was administered
per patient (range, 1 cycle). The patients received an
initial dose of 320 mg/m2, 280 mg/m2 or 250 mg/m2
of vinflunine according to the summary of product
Table 2 Adverse events that occurred in more than 10%
of 102 patients treated with vinflunine
Adverse event All treated patients N = 102, N (%)
All grades Grade 3/4
Constipation 72 (70.6%) 6 (5.9%)
Vomiting 50 (49.1%) 2 (2.0%)
Neutropenia 49 (48.1%) 13 (12.8%)
Abdominal pain 35 (34.3%) 5 (4.9%)
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and 12 patients (11.76%) of the patients received
320 mg/m2, 280 mg/m2 or 250 mg/m2 of vinflunine
respectively.
After a median follow up of 8.9 months, 81 (79.4%)
patients had progressive disease and 66 (64.7%) had died
by any cause. Median progression free and overall sur-
vival for all patients (N = 102) was 3.9 months (2.3-5.5)
and 10 months (7.3-12.8), respectively (Figures 1 and 2).
Time to tumor progression in the whole population wasFigure 1 Kaplan Meier curve by local assessment of progression free
treated with vinflunine.4.3 months (2.6-5.9). Radiological response was evalu-
able in 98 patients. Two patients (2%) achieved a CR, 23
(22.5%) patients had PR, and 42 (41.2%) presented SD as
best response. The clinical benefit rate with vinflunine in
the intent to treat populations was 65.7% of those
treated (Table 3).
Median duration of response for those patients who
achieved a complete or partial response (25 patients) was
9.6 months (CI 95% 6.7 – 12.4 months). Median progres-
sion free survival for those patients with stable disease (42
patients) as best response by RECIST was 5 months (CI
95% 3.7-6.4 months).
Among those with ECOG 0 or 1, median progression
free survival was 7.0 (2.8-11.1) months and 3.1 (2.0-4.2)
months, respectively (HR = 1.49; 95% CI 0.92-2.41: p =
0.102). Those patients with liver metastatic involvement
(17.2%) had a median progression free and overall sur-
vival of 2.3 and 6.1 months, respectively (Figure 3). By
contrast, all patients without liver metastasis (82.8%)
had a median progression free survival of 4.4 monthssurvival for the 102 patients with platinum resistant TCCU
Figure 2 Kaplan Meier curve by local assessment of overall survival for the 102 patients with platinum resistant TCCU treated with
vinflunine.
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those patients asymptomatic at start of vinflunine
(ECOG 0) had an overall survival of 13.2 months that
compared favorably with the overall survival achieved
by those patients with ECOG 1 or 2 (6.7 months)
(Figure 4).Table 3 Overall Response Rates according to the
investigators
Best response Investigator assessment N (%)
Complete response 2 (2.0%)
Partial response 23 (22.5%)
Stable disease 42 (41.2%)
Progressive disease 31 (30.4%)
Not evaluable 4 (3.9%)
Overall tumor response rate (CR + PR) 25 (24.5%)
Clinical benefit rate (CR + PR + SD) 67 (65.7%)Discussion
The disseminated platinum-resistant TCCU population
is clearly an unmet clinical need which, up to now, has
not been solved. Modest activity in terms of overall sur-
vival in the pivotal trial means that patients’ access to
this drug might not be as fluid as it should. Therefore, a
high proportion of patients with advanced TCCU will
not receive any active treatment after failure of prior
platinum-containing schemes.
Our study demonstrates that vinflunine is an active and
safe drug for patients with platinum-resistant urothelial
carcinomas treated in routine daily practice. The efficacy
that we obtained was similar to the results achieved in the
registration trial. In this respect, we reported an overall
response rate of 24.5% which compares more than favor-
ably with that achieved in the registration trial (8.1%).
Disease control rate was also greater in our study (65.7%)
than in the pivotal trial (41.1%). Two (2%) of the patients
that received second-line vinflunine for advanced TCCU
achieved a confirmed CR.
Figure 3 Kaplan Meier curve by local assessment of overall survival according to the presence of liver metastases.
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free and overall survival; in our series we observed
3.9 months and 10 months, respectively, which compared
favorably to the 3.0 and 6.9 months achieved in the regis-
tration trial. Moreover, we were able to administer more
cycles of vinflunine (4) to our patients than were adminis-
tered to those in the pivotal trial (3). This is of particular
importance since it reflects the good safety profile and
management of vinflunine in daily clinical practice where
comorbidities and patient performance status are very
different to those in the selected patients recruited for
industry-sponsored trials. To support the concept of vin-
flunine’s good tolerability in daily clinical practice we can
compare several adverse events grade 3 or 4 with those ob-
served in the pivotal trial, such as constipation (5.9% vs
16.1%), vomiting (2% vs 2.8%), neutropenia (12.8% vs 50%),
and abdominal pain (4.9% vs 4.0%). Nevertheless, since the
image evaluation techniques were performed according to
local practices, there could have been a delay in the evalu-
ation timeline of responses in comparison with the fixed
timeframe executed in the pivotal trial. This fact may affect
the duration of vinflunine treatment in our series.The presence of visceral metastasis, a poor performance
status (ECOG> 0), and low basal hemoglobin levels (<10
gr/dl) are considered poor prognostic factors for overall
survival in patients with metastatic TCCU who experi-
enced treatment failure with the first-line platinum-based
regimen included in the phase III vinflunine trial [37,38].
We also saw that impact on prognosis in our patients:
those patients with ECOG 1 or 2 had less progression
free and overall survival than those with ECOG 0 at
baseline (3.1 months and 6.7 months vs 7.0 months and
13.2 months). The same was found with respect to the
presence of visceral metastasis at the time of entering
into the study. Those patients who had visceral metasta-
sis in lungs or liver had poorer median progression free
and overall survivals (2.6 months vs 7.1 months) than
those who only had lymph nodes and/or bone metastasis
involvement (6.1 months vs 11.3 months).
Similarly, patients with liver involvement had a statisti-
cally significant worst progression free survival (2.3 vs.
4.4 months; HR 1.66 CI95% 1.02-2.7: p = 0.039) and over-
all survival (6.1 vs. 11.7 months; HR 2.44 CI 95% 1.41-
4.23: p = 0.001) than those without liver involvement.
Figure 4 Kaplan Meier curve by local assessment of overall survival according to ECOG performance status at start of vinflunine.
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tial dose used with clinical outcome nor a need for a fur-
ther dose reduction.
The present study has several design limitations, such
as being a retrospective analysis with no control group,
efficacy and safety monitoring were not pre-specified
(the investigator’s own practice) and the bias in the selection
of patients who were candidates for a second-line treatment
approach, among others. However, the elevated rate of
baseline comorbidities of patients included in the study, the
high rate of distant metastasis and the high proportion of
ECOG >0 make this group a true reflection of the general
population of metastatic TCCU patients. Nevertheless, we
lacked the candidate biomarkers of prospectively designed
vinflunine trials which may have allowed us to better select
patients who would have had greater possibilities of a
higher clinical benefit. Along these lines, the Spanish On-
cology Genitourinary Group (SOGUG) cooperative group
is currently exploring the correlation between efficacy, anti-
angiogenic tissue markers and epithelial-mesenchymal tran-
sition tissue markers in those patients who gave special
informed consent and were treated with vinflunine.Two similar experiences of vinflunine use in daily rou-
tine practice in Germany and France were recently re-
ported in an abstract form [39,40]. German colleagues
reported a response rate of 23.4% with a median overall
survival of 7.7 months and an average of 4.7 cycles ad-
ministrated to 77 TCCU patients. French colleagues re-
ported the results from 134 patients who received a
median of 5 (1 to 23) cycles to reach a median progres-
sion free survival of 4.2 months, an overall response rate
of 22% and an overall survival of 8.2 months. Cross re-
port comparison seems to confirm that the outcomes
achieved in the registration trial are reproducible in rou-
tine daily practice.
In conclusion, the results from this study confirm that the
efficacy and safety of vinflunine in second-line treatment of
metastatic TCCU patients who have failed platinum-based
schemes in a trial population can be reproduced in an unse-
lected group of patients with metastatic TCCU. Compared
to published data, those patients treated with vinflunine in
daily clinical practice show similar results to those previ-
ously reported. The patients included in our study repre-
sent an unselected group with metastatic TCCU and,
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can be reproduced in the general population. No relevant
differences in toxicity patterns and length of treatment
were observed. These results are encouraging and imply
that the clinical trial results seen with vinflunine could
be translated into routine clinical practice. Taking these
results into consideration, vinflunine seems to be a rea-
sonable option in daily clinical practice for patients with
advanced TCCU who experience progression after first-
line platinum-based chemotherapy.
Conclusions
Patients who progress under or after platinum-based
chemotherapy schemes have a very poor prognosis with
a life expectancy of less than 6 months. Vinflunine is the
only drug which has been approved, at least in Europe,
for the treatment of these patients. Clinical setting re-
producibility of the outcomes achieved in pivotal clinical
trials is sometimes troublesome. We performed a retro-
spective analysis of the clinical outcome in terms of ac-
tivity and safety in 102 unselected, consecutively treated
patients with metastatic TCCU who had previously pro-
gressed after one prior platinum-containing regimen. Pa-
tients received a median of 4 cycles of vinflunine
treatment (range between 1 and 18). Median progression
free and overall survival for all patients (N = 102) was
3.9 months (2.3-5.5) and 10 months (7.3-12.8), respect-
ively. Time to tumor progression in the intention to
treat population was 4.3 months (2.6-5.9). Radiological
response was evaluable in 98 patients. Two patients (2%)
achieved a CR, 23 (22.5%) patients had PR, and 42
(41.2%) presented SD as best response. Furthermore,
65.7% of patients demonstrated a clinical benefit with
vinflunine. These results of vinflunine in daily clinical
practice resemble those achieved in the pivotal trial. The
toxicity profile was also similar to that reported previ-
ously. Taking all these outcomes into consideration we
believe that the results are encouraging and imply that
the clinical trial results obtained with vinflunine can be
translated into routine clinical practice. Nevertheless,
there is an overwhelming need to incorporate new ob-
jective translational biomarkers that might help us better
select the right treatment for our patients.
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